Top Industry Leaders in the Verrucous Carcinoma Market
Latest Verrucous Carcinoma Companies Update
June 2023: In an attempt to alleviate the severe lack of cancer medications in the country, the U.S. Food and Treatment Administration has approved the temporary importation of an unlicensed chemotherapy treatment from China, according to an update provided to the agency. According to a document, Qilu Pharmaceutical, which manufactures and sells cisplatin injections in China, obtained approval from the FDA a few weeks ago to export the medication to the American market. Qilu is working with Apotex, a Toronto-based business, to distribute 50-milligram vials of cisplatin in the United States. Medical professionals can start placing orders for the medication from their wholesalers. For many years, cisplatin has been a widely accessible generic medication in the United States, supplied by multiple authorized producers. These producers have struggled to meet the demand.
Nov 2023: Presenters from Bristol Myers Squibb's cardiovascular brand will showcase their findings at the American Heart Association's (AHA) annual Scientific Sessions in Pennsylvania. The Phase 3 EXPLORER-HCM study will include new analyses of the efficacy of CAMZYOS® (mavacamten) in patients with and without gene variants, as well as new real-world analyses of patients with symptomatic NYHA class-III–III obstructive hypertrophic cardiomyopathy (HCM) receiving CAMZYOS in clinical practice. These clinical trial data will be featured. New data from the Bristol Myers Squibb-Pfizer Alliance will also be made available. This data will show how different geographic regions and racial groups in the United States utilize oral anticoagulants differently amongst commercially insured individuals who have non-valvular atrial fibrillation (NVAF) who are at high risk of stroke.List of Verrucous Carcinoma Key companies in the market
- Bristol-Myers Squibb Company (US)
- Qilu Pharmaceutical Co., Ltd. (Asia Pacific)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Eli Lilly and Company. (US)
- F. Hoffmann-La Roche Ltd (Europe)
- Merck & Co., Inc. (US)
- Novartis AG (Europe)
- Pfizer Inc. (US)